Drug intelligence / Profile preview

AK14

Development stage: Preclinical
Lead developer: Aetas Pharma
Modality: Small Molecules
Administration: Oral

Overview

AK14 is a pharmaceutical candidate being developed by Aetas Pharma for the treatment of overactive bladder (OAB). The drug utilizes Aetas Pharma's proprietary **Aetas-DDS** technology, a drug delivery system designed to provide sustained-release characteristics. This technology typically involves the use of biodegradable polymers to control the release rate of the active pharmaceutical ingredient, aiming to maintain therapeutic plasma concentrations over an extended period, improve patient compliance, and minimize peak-related side effects. As of 2024, AK14 is in the preclinical stage of development.

Beyond the preview

Go deeper on AK14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK14.

Explore the full profile